NHI
National Health Investors Inc Real Estate Real Estate Investment Trusts Russell 3000
$67.04Close
$3.2BMarket cap
$63.96 – $88.9452-week range
Nov 9, 2026Next report · after the close
Highlights
Strengths
- Earnings growing EPS +45% year on year, faster than the quarter before (+34 pts)
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 24 · weaker than 76% of stocks over 12 months
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
25%
1wk
0.0%
price change
1mo
up 2.1%
price change
12-month return
down 8%
market up 11% ·
its own down 17%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
22.8×
price / earnings
PEG
—
P/E / EPS growth
P/B
2.1×
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 47%
year on year
EPS growth
up 45%
latest quarter · +34 pts
Sales growth
up 215%
latest quarter · +49 pts
ROE
up 10%
return on equity
Free cash margin
down 72%
-$57.5M FCF
D/E
0.76
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
2.1%
$1.41 a day · 2×ATR $64.22
RS
24 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.79
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 1 of 8
- Within 25% of the 52-week high: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 5.7% over the year, from 46m to 48m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026-8% vs market2 sessions after results
Financials
- Net 178%
- Free cash -72%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $35.8M | $48.8M | $54.4M | $80.1M |
| Net income | $185.1M | $111.8M | $66.4M | $135.7M | $138.0M | $142.2M |
| Net margin | — | — | 186% | 278% | 254% | 178% |
| Earnings per share | $4.14 | $2.44 | $1.48 | $3.13 | $3.13 | $3.02 |
| Free cash flow | $115.4M | $160.5M | $174.3M | $134.9M | $49.8M | -$57.5M |
| Free cash margin | — | — | 487% | 276% | 92% | -72% |
| Cash | $43.3M | $37.4M | $19.3M | $22.3M | $24.3M | $19.6M |
| Long-term debt | $1.5B | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B |
| Shareholders' equity | $1.5B | $1.5B | $1.3B | $1.3B | $1.4B | $1.5B |
| Shares outstanding | 45.19m | 45.85m | 43.39m | 43.41m | 45.69m | 48.30m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 27, 2026 | Director or officer change ↗ |
| Aug 10, 2026 | Regulation FD ↗ |
| Aug 10, 2026 | Regulation FD ↗ |
| Aug 10, 2026 | Results ↗ |
| Jul 27, 2026 | Director or officer change ↗ |
| Jul 1, 2026 | Agreement ended · Acquisition or disposal ↗ |
| Jul 1, 2026 | Director or officer change ↗ |
| Jun 1, 2026 | Other events ↗ |
| May 29, 2026 | Shareholder vote ↗ |
| May 4, 2026 | Regulation FD ↗ |
| May 4, 2026 | Regulation FD ↗ |
| May 4, 2026 | Results ↗ |